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Abstract
Background: MicroRNAs are small non-coding RNAs involved in the regulation of gene expression on a posttranscriptional
level. These regulatory RNAs have been implicated in numerous cellular processes and are further deregulated in different
cancer types, including breast cancer. MiR-92a is part of the miR-17,92 cluster, which was first reported to be linked to
tumourigenesis. However, little is known about the expression of miR-92a in breast cancer and potential associations to
tumour properties. The expression of miR-92a was therefore characterized in 144 invasive breast cancer samples using in
situ hybridization and related to clinico-pathological data as well as to selected key properties of the tumour stroma,
including the presence of macrophages (CD68) and cancer activated fibroblasts (alpha-SMA).
Methodology/Principal Findings: To measure miR-92a levels, an in situ hybridisation protocol was developed and validated
using cell lines and miR-92a inhibitors. The expression in the tumour samples was objectively evaluated using digital image
analysis program subtracting background activities. We found that the miR-92a expression varied between tumours and
was inversely correlated to tumour grade (r=20.276, p=0.003) and recurrence-free survival (p=0.008) and provided
independent prognostic information in multivariate Cox analysis (HR: 0.375, CI: 0.145–0.972, p=0.043). MiR-92a was
moreover inversely correlated to the number of infiltrating macrophages in the tumour stroma (r=20.357, p,0.001), and
downregulation of miR-92a promoted cell migration (p,0.01).
Conclusions/Significance: This study demonstrates that downregulation of miR-92a in breast cancer is linked to key
epithelial and stromal properties as well as clinical outcome.
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Introduction
MiRNAs (microRNAs) are a class of non-coding endogenously
expressed RNAs that regulate mRNAs on a posttranscriptional
level. These short (,22 nucleotides) gene regulatory RNA
molecules are involved in numerous cellular processes including
proliferation, metabolism, cell death, cell motility and develop-
ment [1]. MiRNAs have also been linked to cancer, mainly due to
proliferation and apoptosis regulatory functions for some miRNAs,
but also based on the localization of miRNAs to fragile sites in the
genome [2]. MiRNA expression profiles that can further
distinguish between normal breast tissue and breast cancer have
been presented by several groups [3,4]. These differences in
expression for certain miRNAs in breast cancer suggests that
miRNAs can be useful biomarkers for breast cancer progression
and clinical course or might even be key molecular events in the
transformation process. Since each miRNA is believed to regulate
multiple mRNAs, alterations of one miRNA will have impact on
several target genes in a number of different pathways, suggesting
that it is more efficient to target or monitor a single miRNA than
one individual mRNA [5].
MiR-92a is part of the miR-17,92 cluster, consisting of seven
miRNAs (miR-17-5p, miR-17-3p, miR-18a, miR-19a, miR-19b,
miR-20a and miR-92a), first described as an oncogenic miRNA
cluster involved in B-cell lymphoma [6]. However, other studies
have reported contrasting roles for these miRNAs, both as a
cluster and as individually miRNAs [7]. Among the members in
the cluster, miR-92a is the least characterized subunit. A potential
link to tumourigenesis has originated from studies of miR-92a
levels in the plasma of patients with different types of malignancies.
In acute leukemia, plasma level of miR-92a could successfully
distinguish between leukemic patients and healthy donors [8], and
similar observations have been described in colorectal cancer [9].
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e36051In patients with hepatocellular carcinoma, miR-92a has been
reported to be overexpressed in the cancerous tissue whereas levels
of miRNA in plasma were lower compared to healthy donors [10].
The role of miR-92a in breast cancer has not been fully clarified
and a relationship to the miR-17,92a cluster does not necessarily
suggest that all these miRs have oncogenic properties. Zhang et al
also demonstrated that the miR-17,92a cluster was deleted in
21.9% of analyzed breast cancer samples, indicating that miRNA
alterations can differ depending on cancer type [11].
In this study we developed an in situ hybridization method for
the detection of miR-92a in formalin fixed tumour material and
investigated the expression in a tissue microarray consisting of 144
breast cancer samples. Objective digital image analysis was used to
delineate mir-92a expression and interestingly downregulation of
miR-92a was inversely associated to tumour grade, recurrence-free
survival and the presence of tumour infiltrating macrophages. In
vitro studies also revealed an increase in cell migration after
downregulation of miR-92a. These novel data suggest a possible
interaction between epithelial miR-92a levels and key tumour
properties and aggressiveness as well as links to immune cells in the
tumour stroma.
Results
Validation of the miR-92a in situ hybridization method
In order to validate the accuracy of the miR-92a detection
probe, the breast cancer cell line MDA-231 was transfected with a
miR-92a inhibitor and downregulation was confirmed by qRT-
PCR (Figure 1A). In situ hybridization for miR-92a was then
performed using the same batch of cells as for the qRT-PCR.
Digital image analysis software was used to analyze the expression
of miR-92a and confirmed a decreased expression after inhibitor
treatment both visually and by quantification of the staining
intensity using digital image analysis (Figure 1B–C).
Expression of miR-92a in human breast and in breast
cancer
We next performed miR-92a in situ hybridization of a TMA
(tissue microarray) containing 144 breast cancer samples [12].
Figure 2 illustrates the expression of miR-92a in normal breast and
cancer tissue. The staining shows a higher expression of the
miRNA in the normal tissue compared to tumour areas. To
compensate for variations in background staining we used a
negative control probe and hybridized it to a second set of the
TMA. The signal from the negative control was then subtracted
from the miR-92a expression signal for each tumour core,
resulting in a representative miR-92a expression value. The digital
image analysis was performed with the Digital Image Hub
software from Slidepath and generated information about staining
intensity and fraction positive cells in 117 (81%) breast cancer
samples. The missing cases (n=27), which did not contain enough
tissue for analysis, did not differ significantly from the successful
cases regarding age, tumour size and grade, lymph node status,
Ki67, ER/PR/HER2 status and stroma markers (data not shown).
The staining intensity and fraction positive cells for miR-92a were
strongly correlated (Pearson’s chi square correlation=0.968,
p,0.001) and only staining intensity values were used in the
following analyses. Patients were further divided into quartiles
according to expression of miR-92a where quartile 1 (Q1) had the
lowest intensity and quartile 4 (Q4) the highest (Figure 3A).
Hybridization with the miR-92a probe and the negative control
probe of a Q4 tumour followed by image analyses detection is
illustrated in Figure 3B.
miR-92a and clinico-pathological properties and its
cellular role
First, we investigated the association between miR-92a
expression and established clinico-pathological parameters with a
focus on epithelial tumour properties. As presented in table 1,
miR-92a was significantly inversely correlated to tumour grade
(Spearman’s r=20.276, p=0.003) whereas there was no
significant link to proliferation, ER-status, tumour size or lymph
node positivity. We next analyzed the potential link between miR-
92a and breast cancer recurrence. Kaplan Meier analysis clearly
illustrates that the patients with the highest expression of miR-92a
(Q3 and Q4) had a better outcome compared to patients with
lower miR-92a expression (Q1 and Q2) expression (Figure 4A,
p=0.065). This difference in recurrence was highly significant
when merging the two lowest quartiles into low miR-92a
expression and the two highest into high miR-92a expression
(p=0.008) as presented in Figure 4B.
Figure 1. Validation of miR-92a in situ hybridization probe. A) Downregulated of miR-92a in MDA-231 cells was validated and confirmed by
qRT-PCR. B) Detection of miR-92a using in situ hybridization in MDA-231 cells after downregulation of miR-92a. Lower panel shows the definition of
positive pixels identified by the digital image analysis program. C) Quantification of positive pixels by the image analysis program.
doi:10.1371/journal.pone.0036051.g001
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miR-92a, we performed a univariate Cox proportional hazard
regression analysis and observed a significant benefit for patients
with tumours displaying high expression of miR-92a (p=0.012,
hazard ratio=0.328, CI: 0.138–0.781) (Table 2). We also
performed a multivariate Cox proportional hazard regression
analysis adjusting for known prognostic factors as age, tumour size,
lymph node status, tumour grade and ER-status. Even in this
model, patients with high levels of miR-92a had a significantly
(p=0.043) lower risk of recurrence, with a hazard ratio of 0.375
(CI: 0.145–0.972), compared to the patients with low expression of
miR-92a (Table 3). These data demonstrate that miR-92a adds
independent prognostic information in breast cancer and patients
with high levels of miR-92a have better clinical outcome than
patients with low levels.
Inhibition of mi92a in the breast cancer cell line MDA-MB-231
in comparison to control cells showed a highly significant increase
in migration (p,0.01) which was not caused by increased
proliferation (Figure 5). These data may provide a mechanism to
support our observations within primary breast cancer samples
whereby loss of miR-92a was associated with poor clinical
outcome.
miR-92a and tumour stroma properties
We next investigated the association between miR-92a and a
selection of key malignant properties within the tumour stromal
compartment, e.g. the presence of cancer activated fibroblasts and
macrophages. Activated fibroblasts were defined as smooth muscle
actin a (SMAa) positive and macrophages were defined as CD68-
positive cells. There was no link between miR-92a and SMA-
positivity in fibroblasts (p=0.962) but interestingly a strong inverse
link to macrophage content was observed (Spearman’s
r=20.357, p,0.001) (Table 1). As illustrated in figure 6, the
lowest quartile of CD68-positive tumours had a substantially
higher miR-92a content compared to a stepwise reduction in miR-
92a levels with increasing CD68 macrophage contents indicating
an inverse link between miR-92a expression and macrophages.
This suggests a role for miR-92a in the interaction between
epithelial cells and immune cells in the tumour stroma
compartment.
Discussion
In this report we have developed and validated an in situ
hybridization method for the detection of miR-92a in breast
cancer samples and successfully linked its expression levels in
breast cancer to several key tumour properties. In situ hybridiza-
tion is a powerful method for the detection and localization of a
specific nucleotide sequence within a preserved cellular and tissue
context, however the method is often debated due to issues with
specificity and demanding optimization procedures [13]. Our
results nevertheless clearly confirm that this approach, although
challenging, can be valuable for the detection of miRNA in
formalin fixed material of cancer samples arranged in TMAs.
Figure 2. MiR-92a expression in normal breast and breast
cancer samples. A) and B) Two examples of miR-92a expression in
normal breast tissue compared to tumour areas.
doi:10.1371/journal.pone.0036051.g002
Figure 3. MiR-92a expression in breast cancer samples. A) In situ
hybridization was performed on a breast cancer tissue microarray using
a detection probe for miR-92a and a negative control probe. Tumours
were divided into quartiles 1–4 (Q1–Q4) based on the staining intensity
(Q1=weakest staining, Q4=strongest staining). 206 magnification. B)
Example of positive pixel definition of representative Q4 tumour stained
with miR-92a probe and negative control probe. 406magnification.
doi:10.1371/journal.pone.0036051.g003
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hybridization is the length of the detection probe. For mRNA in
situ hybridization, an oligonucleotide probe is generally 40–50 base
pairs long. A miRNA is approximately 22 nucleotides long which
makes it unfeasible to use a standard oligonucleotide probe [13].
Therefore, we alternatively used LNA (locked nucleic acid)-
enhanced microRNA detection probes. These probes are exactly
complimentary to the target miRNA and the incorporated LNA
molecules leads to a stable probe:miRNA duplex increasing the
success rate of the detection. Another concern is the amount of the
target miRNA present in the tissue. Low amounts of specific
miRNAs are difficult to detect due to loss of miRNAs by diffusion
out of the tissue sections during the preparation of the tissue. In
this study, the retention of miRNAs was improved by introducing
an additional fixation step to the procedure using 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC), which creates an
irreversible cross-link between the 59 phosphate of the miRNA
and the amino groups in the protein side chains [14]. To further
improve the detection of low abundant miRNAs, we used double-
DIG labelled probes in order to enhance the detection signal. Even
though we have developed a functional miRNA in situ hybridiza-
tion protocol for miR-92a, we were unable to obtain successful
results for two additional miRNA probes (data not shown),
elucidating the challenges associated with the method.
For validation, in situ hybridization probes were tested in cells
transfected with a specific inhibitor targeting the candidate
Table 1. Distribution of miR-92a expression in breast cancer tumours according to clinico-pathological parameters.
miR-92a staining intensity
Q1 Q2 Q3 Q4
Variable N=29 N=30 N=28 N=30 P{
Median age, y (range) 59 (35–90) 67,5 (49–97) 66,5 (44–91) 62 (34–87) 0.337{
Tumor size, mm
#20 13 11 16 19 0.065
$21 16 19 12 11
Lymph node status
Negative 16 11 14 16 0.984
Positive 9 17 11 12
NHG
I 1 2 4 9 0.003
II 10 14 16 10
III 18 14 8 11
Ki67-positive, %
0–10 2 2 0 1 0.523
11–25 6 11 14 10
.25 17 14 10 15
ER-positive, %
,10 6 4 2 5 0.549
.10 23 26 26 25
PR-positive, %
,10 12 11 6 8 0.127
.10 17 19 22 22
HER2 gene amplification
No 24 28 26 28 0.160
Yes 4 2 2 1
CD68+ cells (macrophages)
Q1 3 3 9 1 4 ,0.001
Q2 5 6 8 6
Q3 7 1 4 4 6
Q4 1 0 3 6 3
SMA intensity
1 1 5 2 1 0.885
21 8 1 5 1 6 1 7
37 5 3 6
{Correlations were calculated using Spearman’s r(two-sided) unless otherwise specified. P values were not adjusted for multiple testing.
{Kruskal-Wallis test (two-sided).
doi:10.1371/journal.pone.0036051.t001
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signal in parallel with a miRNA decrease by qRT-PCR were
selected for further analysis and were considered to be specific. In
order to further assure the accuracy of the measured miRNA
expression in the tissue, we normalised the detected miR-92a
probe signal by subtracting a background signal. To do so, a
second set of TMAs were hybridized with a control probe which is
not complementary to any known microRNA and thus would not
specifically bind to the tissue. Any detected signal therefore
indicates background noise. The use of proper controls and
evaluating the expression intensity objectively with digital image
analysis secured the quality and reliability of the miRNA content
analyses in the tissue specimens in our study.
The expression pattern of miRNA is complex and seems to be
cell and tissue specific and also varies in different malignancies
[15]. One specific miRNA can have diverse expression levels in
different types of tumours probably depending on the tissue and
origin of the tumour (tumour properties). Also the regulation of
miRNA expression itself may be aberrant in some tumours. MiR-
125b was shown to be lost in breast cancer [3] whereas it is
frequently upregulated in pancreatic cancer [16]. Similar
contrasting results for other malignancies and miRNAs seem
likely and it is therefore important to carefully clarify the
expression of various miRNAs in specific tumour types separately.
MiR-92a is part of a reported oncogenic miRNA cluster and has
been demonstrated to be upregulated in hepatocellular carcinoma
[6,10]. However, it has also been reported that the genomic
region, in which miR-92a is located, is often deleted in breast
cancer [11]. Here we observed that miR-92a expression varied
amongst different breast cancer samples. Tumours displaying low
miR-92a levels were associated with high tumour stage and poor
recurrence-free survival suggesting that miR-92a is a potential
marker for tumour progression. In fact, multivariate analysis
including age, tumour size and stage, lymph node and ER status
revealed that miR-92a is an independent prognostic marker.
Additionally we have observed that miR-92a is present in
normal breast ducts and lobular units suggesting that miR-92a
plays a physiological role in the normal breast tissue and is most
likely downregulated in a fraction of breast cancer. The functional
consequences of a loss of miR-92a have previously not been
described. In this study we observed that downregulation of miR-
92a in breast cancer cells resulted in increased cell migration, and
it has been predicted that miR-92a affect genes that are involved
in the regulation of the actin cytoskeleton and MAPK signalling
pathway. Both processes are well known to be associated with
cancer [17].
In addition to the link to tumour differentiation and disease
recurrences, miR-92a was strongly and inversely correlated to the
amount of infiltrating macrophages in the tumour stroma. It is
becoming evident that the interplay between the components of
the stromal compartment and the epithelial cells is of great
importance and might influence both tumour initiation and
progression [18]. Bandres et al demonstrated that miR-451 was
directly targeting the pro-inflammatory cytokine macrophage
migration inhibitory factor (MIF), which activates several
macrophage functions [19,20]. This potential crosstalk between
miRNA expression in the epithelial cells and the response in cells
located in the surrounding stroma is potentially relevant for miR-
92a. Whether miR-92a has a gene target linked to macrophage
infiltration remains to be further investigated.
In summary, in this study we present entirely novel data about
the expression of miR-92a in breast cancer using an in situ
hybridization approach. For the first time we show that miR-92a is
linked to tumour stage and disease-free survival and although
patient cohort was small, miR-92a expression provided indepen-
dent prognostic information in a multivariate analysis. Strikingly,
miR92a expression was also associated with macrophage infiltra-




The study was approved by the Ethics Committee at Lund
University (reference no 447-07) in Lund, Sweden. The ethics
committee considered that informed consent was not to be
required other than by the opt-out method. The data was analyzed
anonymously.
Figure 4. Recurrence-free survival among breast cancer patients according to miR-92a expression. A) Tumours were divided into four
groups based on the staining intensity of miR-92a and recurrence-free survival for the patients was determined, p=0.065. B) Recurrence-free survival
analysis after merging of tumours in Q1–Q2 and Q3–Q4, p=0.008.
doi:10.1371/journal.pone.0036051.g004
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The breast cancer specimens used in this study were obtained
from 144 patients undergoing surgical resection at Malmo ¨
University Hospital, Malmo ¨, Sweden, between 2001 and 2002.
The median age at diagnosis was 65 years, and the median follow-
up time for disease-specific and overall survival was 78 months. 31
(21%) of all patients in this cohort received adjuvant chemother-
apy. Additional clinical information has been described previously
[12,21]. The study was approved by the regional ethical
committee in Lund, Sweden.
Cell culture and transfection
Validation of in situ hybridization probe. The breast
cancer cell line MDA-MB-231 was maintained at 37uCi na
humidified atmosphere with 5% CO2 and grown in RPMI 1640
growth medium supplemented with 10% fetal bovine serum (FBS),
1% sodium pyruvate and 1% penicillin and streptomycin. Cells
were seeded 24 h before transfection. Lipofectamine 2000
(Invitrogen, CA, USA) was used for transfection of 20 nM
miRNA Inhibitor (Exiqon, Vedbaek, Denmark) into the cells
according to the manufacturer’s instructions. The growth medium
was changed to serum-containing medium 6 h after transfection.
Cells were harvested 48 h after transfection for migration,
proliferation and RNA extraction for qRT-PCR validation as
well as cells were fixed and embedded in paraffin for validation of
the in situ hybridization probe. Total RNA, including small RNAs,
was extracted using the miRNeasy kit (Qiagen, Sollentuna,
Sweden) according to the manufacturer’s instructions with the
exception of using 70 ml BCP (1-bromo-3-chloro-propan) instead
of choloform. RNA concentrations and purity, measured by the
ratio c260/c280 (2.08–2.09) were verified by measuring
absorbance on the NanoDrop Spectrophotometer ND-1000.
500 ng of RNA was reverse-transcribed using Megaplex Primer
Pool A. Individual TaqMan MicroRNA Assays (Applied
Biosystems, CA, USA) were used for quantification of miR-92a
and the endogenous controls RNU48 and MammU6 snRNA
according to the manufacturer’s instructions. The qRT-PCR was
carried out using 7300 Real Time PCR Systems (Applied
Biosystems) under the conditions: 10 min at 95uC followed by
40 cycles of 95uC for 15 sec and 60uC for 60 sec. The comparative
threshold cycle (Ct) method was used for calculation of miRNA
expression.
Migration assays
Cell migration was routinely carried out in 8 mm-pore
polycarbonate membrane Transwell chambers with a diameter
of 6.5 mm (Corning, Inc. Corning, NY). The membranes were
incubated in 150 ml serum-free RPMI 1640 for an initial
equilibrium period of 1 h. Cells were resuspended in serum-free
medium (1610
6 cells/ml) and 50,000 cells were added to each
migration chamber. The chambers were placed into wells
containing 600 ml 10% FCS medium and cells were allowed to
migrate for 5 h following inhibition of mi92a. Cells remaining in
the chamber were removed with a cotton swab and the migrated
cells situated on the lower side of membranes were fixed for
15 min in PBS containing 4% paraformaldehyde. Membranes
were cut and mounted on glass slides for DAPI staining and
counted using a fluorescent microscope (cells were counted in
106-magnification fields representing the composition of the
membrane and the average percentage of cells determined). Assays
were repeated three times.
Proliferation assays
Growth curve was monitored using Alamar blue (Invitrogen).
Cells were seeded out in 96 well plates at 2.5610
4/ml
concentration (2500 cells/well) 48 h post-transfection. Cell
viability was measured every 24 h for 4 days by adding 2%
Alamar blue and fluorescence was read at 540/590 nm after 1 h
incubation. Optical density values were normalised to day 1
reading.
Tissue specimens and immunohistochemistry
All included cases were histopathologically re-evaluated and
TMAs (tissue microarrays), containing duplicate 1.00 mm cores,
were constructed from areas with invasive breast cancer using a
Table 2. Univariate Cox proportional hazard regression
model of the risk of recurrence according to clinico-
pathological factors and miR-92a expression.
Recurrence-free
survival
Variable HR 95% CI P
Age continuous 1.038 1.008–1.069 0.012
Tumour size #20 mm 1.0
$21 mm 3.141 1.391–7.096 0.006
Lymph node status negative 1.0
positive 6.701 2.523–17.795 ,0.001
Tumour grade (NHG) I+II 1.0
III 3.363 1.561–7.244 0.002
ER ,10% 1.0
.10% 0.275 0.125–0.604 0.001
miR-92a Low 1.0
High 0.328 0.138–0.781 0.012
NHG=Nottingham Histological Grade; ER=estrogen receptor; HR=hazard
ratio; CI=confidence interval.
doi:10.1371/journal.pone.0036051.t002
Table 3. Multivariate Cox proportional hazard regression
model of the risk of recurrence according to miR-92a
expression adjusted for clinico-pathological factors.
Recurrence-free
survival
Variable HR 95% CI P
Age continuous 1.038 1.002–1.076 0.041
Tumour size #20 mm 1.0
$21 mm 1.923 0.657–5.633 0.233
Lymph node status negative 1.0
positive 5.686 1.863–17.358 0.002
Tumour grade (NHG) I+II 1.0
III 0.774 0.252–2.371 0.653
ER ,10% 1.0
.10% 0.202 0.063–0.645 0.007
miR-92a Low 1.0
High 0.375 0.145–0.972 0.043
NHG=Nottingham Histological Grade; ER=estrogen receptor; HR=hazard
ratio; CI=confidence interval.
doi:10.1371/journal.pone.0036051.t003
MiR-92a in Breast Cancer
PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e36051tissue array machine (Beecher Instruments, Microarray Technol-
ogy, MD, USA). Briefly, 4 mm thick TMA sections were mounted
onto glass slides and deparaffinised followed by antigen retrieval
using Dako’s PTLink (DAKO, Glostrup, Denmark). Immunohis-
tochemistry was then performed using Dako’s Autostainerplus
with the EnVisionFlex High pH-kit (DAKO) with the following
antibodies: ERa (DAKO, M7047 1:50), PR (DAKO M3569
1:400), Ki-67 (DAKO M7240 1:200), CD68 (DAKO M0876
1:1500), aSMA (DAKO M0851 1:1000). Detailed data on ER and
PR analyses have been published previously [21]. CD68 was used
as a pan-macrophage marker and the total amount of CD68-
positive cells within the tumour area in the TMA cores were
manually calculated. Alpha-SMA was used to detect cancer
activated fibroblasts adjacent to invasive breast cancer cells and
was scored according to the proportion of positive fibroblasts into
three subgroups (negative to low, intermediate or high) with the
following distribution; 9 (9%), 66 (69%), 21 (22%). All immuno-
histochemistry scoring was performed independently of a pathol-
ogist and a research associate without knowledge of pathological
and clinical data.
MiRNA in situ hybridization
FFPE (formalin-fixed paraffin-embedded) sections (4 mm) from
the TMA were mounted on glass slides, deparaffinised with xylene
and rehydrated to DEPC treated water through a graded series of
ethanol (100%, 70%, 50% and 25%) and left in PBS for 10 min.
After permeabilization in 0.1% Triton X-100 in PBS for 10 min,
the sections were washed in PBS (265 min) and then treated with
Proteinase K (10 mg/ml) during 5 min at 37uC, followed by
rinsing 2630 sec in PBS. The tissue was first post-fixed in 4% PFA
(pH 9.0, 10 min), rinsed with 0.2% glycine in PBS for 30 sec, and
then a second post-fixation, using EDC (1-ethyl-3-(3-dimethyla-
minopropyl) carbodiimide) was performed as followed: The
sections were preincubated in 0.13 M 1-methylimidazole,
300 mM NaCl (pH 8.0) for 2610 min before Bio-Rad’s adhesive
frames (Frame-Seal) were mounted on the slides and 500 ml of the
EDC fixation solution (176 ml EDC in 10 ml 0.13 M 1-
methylimidazole, 300 mM NaCl (pH 8.0)) was added to each
slide and incubated at room temperature for 1.5 h. After washing
in 0.2% glycine in PBS for 30 sec and PBS for 263 min, the
sections were acetylated (5 min in 0.1 M TEA (Triethanolamine),
0.9% NaCl) followed by 5 min in the same buffer with the
addition of 0.5% acetic anhydride). The slides were then rinsed in
26SSC for at least 5 min before they were preincubated for 2 h
with hybridization solution (Sigma-Aldrich, MO,USA) at 6uC
under Tm for the probes in a humid chamber. At the same
temperature, hybridization was performed using double DIG-
labelled LNA
TM-enhanced probes (Exiqon) incubated over night
with a final probe concentration of 2.5 nM for both the negative
control and the test (miR-92a) probe. After stringent wash with
0.16SSC at 4uC for 5 min, rinsed 5 min in PBS, and the
endogenous peroxidase activity was quenched with H2O2
(15 min), the slides were washed 363 min with PBS and incubated
with anti-digoxigenin AP-conjugate (Roche, Stockholm, Sweden),
followed by Nitro blue tetrazolium chloride with NBT/BCIP (5-
bromo-4-chloro-3-indolyl phosphate, toluidine salt) detection and
finally the slides were mounted with mounting media (DAKO).
Figure 5. Cellular properties of miR-92a in breast cancer cell line MDA-231. Downregulation of miR-92a in MDA-231 cells led to in increased
migration (A) but did not affect the proliferation of the cells (B).
doi:10.1371/journal.pone.0036051.g005
Figure 6. Inverse link between CD68-positive macrophages
and miR-92a expression. Tumours were divided into quartiles based
on number of CD68-positive cells (macrophages) and compared to miR-
92a staining intensity.
doi:10.1371/journal.pone.0036051.g006
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The TMA slides were scanned using a Leica SCN400 scanner
(Leica Microsystems, Milton Keynes, UK) and uploaded and
archived on the web-enabled digital slide management system,
SlidePath’s Digital Server (Slidepath, Dublin, Ireland). The slides
were evaluated on-line by a pathologist and representative tumour
regions were selected for analysis. Identical areas for the slides
hybridized with the negative control probe and the miR-92a probe
were annotated. SlidePath’s Tissue IA (Image Analysis) system was
used to determine the miR-92a algorithm which includes a colour
definition file to define positive staining in the cells. The output
contains quantitative measurements such as staining intensity and
percentage positive pixels for the selected cells.
Statistical methods
All statistical calculations were performed using Statistical
Package for the Social Sciences version 19.0 (SPSS, IL, USA).
Spearman’s rank-order correlation coefficient and Fisher’s exact
test were used to examine statistical significance of associations
between miR-92a expression and other categorical variables. The
Kruskal-Wallis test was used to compare medians for continuous
variables. Recurrence-free survival (RFS), defined by breast
cancer-specific death, distant, regional and local recurrences,
was estimated using Kaplan-Meier plots and log-rank tests. A Cox
proportional hazard regression model was used for multivariate
analysis. The statistical significance to the migration assays were
calculated using Student’s T-tests. All tests were two-sided. The
presented p values have not been adjusted for multiple testing. P
less than 0.05 was considered statistically significant.
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